Back to Stocks

IDXX

IDEXX LABORATORIES INC /DE
7 filings tracked
healthcarebiotechnologyLARGE ($10B-200B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

IDEXX Laboratories continues to demonstrate the potency of its 'razor-and-blade' business model, reporting a 14.3% surge in total revenue to $1.14 billion for the first quarter of 2026.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the top-line growth, a closer look at the cost structure reveals emerging pressures. Operating expenses climbed 17.4% year-over-year, outstripping revenue growth and effectively neutralizing much of the gross margin expansion.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every IDXX filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a crossroads between fundamental operational dominance and aggressive financial engineering. On one hand, the organic growth in diagnostics and the expansion of the premium instrument base provide a durable moat and a predictable revenue engine. The 14.3% revenue increase and the ability to expand gross margins in an inflationary environment are clear indicators of a strong competitive position. However, the divergence between gross profit growth and operating expense growth suggests that the company is spending more to acquire and maintain its market share. The shift toward higher leverage to fund equity buybacks introduces a new risk variable into an otherwise stable business. Investors must now weigh the exceptional quality of the underlying veterinary diagnostics business against a deteriorating cash conversion cycle and a more leveraged balance sheet.

Selected Quarter

Core Takeaway

IDEXX is scaling its recurring revenue engine through premium instrument placements, but the cost of growth and aggressive buybacks are impacting the balance sheet.

Investor Lens

The trade-off between impressive top-line organic growth and a deteriorating cash conversion cycle.

Watch Next

The repayment or refinancing of the $75 million 2026 Senior Notes due September 4, 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.52Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 5

Diluted EPS increased 17.2% to $3.47, outperforming revenue growth.

earnings beat
80%
bullishMay 5

Gross profit margin expanded by 100 basis points to 63.4%.

margin expansion
60%
bullishMay 5

Aggressive return of capital with $351 million in share repurchases.

buyback
70%
neutralMay 5

Increased utilization of credit facility to fund operations and buybacks.

debt restructure
40%
bullishMay 5

Diluted EPS increased 17.2% to $3.47, outperforming revenue growth.

earnings beat
80%
bullishMay 5

Gross profit margin expanded by 100 basis points to 63.4%.

margin expansion
60%
bullishMay 5

Aggressive return of capital with $351 million in share repurchases.

buyback
70%
neutralMay 5

Increased utilization of credit facility to fund operations and buybacks.

debt restructure
40%
bullishMay 5

Diluted EPS increased 17.2% to $3.47, outperforming revenue growth.

earnings beat
80%
bullishMay 5

Gross profit margin expanded by 100 basis points to 63.4%.

margin expansion
60%
bullishMay 5

Aggressive return of capital with $351 million in share repurchases.

buyback
70%
neutralMay 5

Increased utilization of credit facility to fund operations and buybacks.

debt restructure
40%
bullishMay 5

Diluted EPS increased 17.2% to $3.47, outperforming revenue growth.

earnings beat
80%
bullishMay 5

Gross profit margin expanded by 100 basis points to 63.4%.

margin expansion
60%
bullishMay 5

Aggressive return of capital with $351 million in share repurchases.

buyback
70%
neutralMay 5

Increased utilization of credit facility to fund operations and buybacks.

debt restructure
40%
bullishMay 5

Diluted EPS increased 17.2% to $3.47, outperforming revenue growth.

earnings beat
80%
bullishMay 5

Gross profit margin expanded by 100 basis points to 63.4%.

margin expansion
60%
bullishMay 5

Aggressive return of capital with $351 million in share repurchases.

buyback
70%
neutralMay 5

Increased utilization of credit facility to fund operations and buybacks.

debt restructure
40%
bullishMay 5

Diluted EPS increased 17.2% to $3.47, outperforming revenue growth.

earnings beat
80%
bullishMay 5

Gross profit margin expanded by 100 basis points to 63.4%.

margin expansion
60%
bullishMay 5

Aggressive return of capital with $351 million in share repurchases.

buyback
70%
neutralMay 5

Increased utilization of credit facility to fund operations and buybacks.

debt restructure
40%
bullishMay 5

Diluted EPS increased 17.2% to $3.47, outperforming revenue growth.

earnings beat
80%
bullishMay 5

Gross profit margin expanded by 100 basis points to 63.4%.

margin expansion
60%
bullishMay 5

Aggressive return of capital with $351 million in share repurchases.

buyback
70%
neutralMay 5

Increased utilization of credit facility to fund operations and buybacks.

debt restructure
40%

Filing History

10-QMay 5, 2026
Expand Sequence

The Q1 2026 filing presents a company at a crossroads between fundamental operational dominance and aggressive financial engineering. On one hand, the organic growth in diagnostics and the expansion of the premium instrument base provide a durable moat and a predictable revenue engine. The 14.3% revenue increase and the ability to expand gross margins in an inflationary environment are clear indicators of a strong competitive position. However, the divergence between gross profit growth and operating expense growth suggests that the company is spending more to acquire and maintain its market share. The shift toward higher leverage to fund equity buybacks introduces a new risk variable into an otherwise stable business. Investors must now weigh the exceptional quality of the underlying veterinary diagnostics business against a deteriorating cash conversion cycle and a more leveraged balance sheet.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.